Panelists discuss the expanding clinical development of cretostimogene across multiple NMIBC populations and treatment strategies, highlighting ongoing trials exploring its use as monotherapy and in ...

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting ...

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need ...

Panelists discuss the final BOND-3 trial results, highlighting intravesical cretostimogene’s strong efficacy, durable responses, and excellent safety profile in BCG-unresponsive carcinoma in situ (CIS ...

Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA. There has been an explosion in innovation in the non–muscle invasive bladder cancer (NMIBC) ...

Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial ...

"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive ...